替尔泊肽(Tirzepatide) - 药物靶点：GIPR x GLP-1R_在研适应症：肥胖，超重，2型糖尿病_专利_临床

概要

基本信息

药物类型

合成多肽

别名

Tirzepatide (USAN)、DehydraTECH-替尔泊肽、替西帕肽

+ [8]

靶点

GIPR x GLP-1R

作用机制

GIPR激动剂(胃抑素受体激动剂)、GLP-1R激动剂(胰高血糖素样肽-1激动剂)

治疗领域

内分泌与代谢疾病神经系统疾病呼吸系统疾病+ [9]

在研适应症

肥胖超重2型糖尿病+ [10]

非在研适应症

低血糖终末期肾脏病肝功能衰竭

原研机构

Lexaria Bioscience Corp.

Eli Lilly & Co.

在研机构

Eli Lilly Nederland BV

Eli Lilly & Co.

美国礼来亚洲公司上海代表处

+ [5]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2022-05-13),

2型糖尿病

最高研发阶段(中国)批准上市

特殊审评优先审评 (美国)、快速通道 (美国)

登录后查看首次获批时间轴

序列信息

Sequence Code 1273099312

来源: *****

关联

109

项与替尔泊肽相关的临床试验

NCT06534411 / Not yet recruiting临床3期

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. Once Weekly Versus Tirzepatide 5 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2 Inhibitor or Both

This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.

开始日期2024-11-05

申办/合作机构

Novo Nordisk A/S

NCT06162715 / Not yet recruiting临床2期IIT

GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Feasibility Trial

The goal of this pilot clinical trial is to determine the effectiveness of Tirzepatide in patients with persistent obesity (BMI > 30) 12 months after bariatric surgery (Roux-en-Y Gastric Bypass). The investigators also aim to determine the frequency of side effects with Tirzepatide in this patient population. Patients who take tirzepatide 12 months after bariatric surgery will be compared to patients who receive a placebo.

开始日期2024-10-01

申办/合作机构

Vanderbilt University Medical Center

NCT06485089 / RecruitingN/AIIT

Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers in Women with Obesity and Other Risk Factors for Breast Cancer

Evaluation of biomarkers for risk of developing breast cancer in women with obesity who are using tirzepatide to achieve weight loss.

开始日期2024-10-01

申办/合作机构

University of Kansas

100 项与替尔泊肽相关的临床结果

登录后查看更多信息

100 项与替尔泊肽相关的转化医学

登录后查看更多信息

100 项与替尔泊肽相关的专利（医药）

登录后查看更多信息

508

项与替尔泊肽相关的文献（医药）

2024-12-31·Journal of medical economics

Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia

Article

作者: Al-Omar, Hussain A ; Almodaimegh, Hind S ; Al-Harbi, Ibtisam ; Hassan, Mohamed ; Alzubaidi, Lamya M ; Akhtar, Omar ; Al-Harbi, Bandar ; Omaer, Abubker

BACKGROUND AND OBJECTIVES:

This study presents a budget impact analysis (BIA) conducted in Saudi Arabia, evaluating the cost implications of adopting semaglutide, tirzepatide, or dulaglutide in the management of type 2 diabetes mellitus (T2DM) patients. The analysis aims to assess the individual budgetary impact of these treatment options on healthcare budgets and provide insights for decision-makers.

METHODS:

A prevalence-based BIA was developed using real-world and clinical trials data. The model considered disease epidemiology, medication prices, diabetes management expenses, cardiovascular (CV) complications costs, and weight reduction savings over a 5-year time horizon. One-way and probabilistic sensitivity analyses (OWSA, PSA) were performed to assess the robustness of the results.

RESULTS:

Over a 5-year period, the cumulative budget impact for semaglutide, tirzepatide, and dulaglutide were 85,923,089 USD, 169,790,195 USD, and 94,558,356 USD, respectively. Hypothetical scenarios considering price parity between semaglutide and tirzepatide are associated with financial impacts of 85,923,091 USD and 86,475,335 USD, respectively. In the public sector, semaglutide showed the lowest incidence of 3-point major adverse CV events (3P-MACE), with tirzepatide leading in weight loss and HbA1c reduction, and dulaglutide presenting the highest 3P-MACE rates and least improvements in HbA1c and weight. A breakeven analysis suggested that tirzepatide's list price would need to be $199.91 lower than its current list price to achieve budget impact parity with semaglutide based on currently available evidence. Results from the OWSA suggested that risk reductions for CV events were key drivers of budget impact. PSA results were confirmatory of base-case analyses.

CONCLUSIONS:

CV cost-offsets and drug acquisition considerations may make semaglutide a favorable use of resources for Saudi budget planners and decision-makers. These results were robust to assumptions regarding the list price of tirzepatide.

2024-11-01·Molecular Metabolism

The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice

Article

作者: Drucker, Daniel J ; Matthews, Dianne ; Baggio, Laurie L. ; Cui, Fiona ; Drucker, Daniel J. ; Forny Germano, Leticia ; Wong, Chi Kin ; Rittig, Nikolaj ; Koehler, Jacqueline A ; Koehler, Jacqueline A. ; Cao, Xiemin ; Baggio, Laurie L

OBJECTIVE:

The development of glucagon-like peptide-1 receptor (GLP-1R) agonists for the treatment of type 2 diabetes and obesity has been accompanied by evidence for anti-inflammatory and cytoprotective actions in the heart, blood vessels, kidney, and brain. Whether GLP-1R agonists might be useful clinically for attenuating deterioration of cognitive dysfunction and reducing the progression of Alzheimer's disease remains uncertain.

METHODS:

Here we evaluated the actions of semaglutide and tirzepatide, clinically distinct GLP-1 medicines, in two mouse models of neurodegeneration.

RESULTS:

Semaglutide reduced body weight and improved glucose tolerance in 12-month-old male and female 5XFAD and APP/PS1 mice, consistent with pharmacological engagement of the GLP-1R. Nevertheless, amyloid plaque density was not different in the cerebral cortex, hippocampus, or subiculum of semaglutide-treated 12-month-old 5XFAD and APP/PS1 mice. IBA1 and GFAP expression were increased in the hippocampus of 5XFAD and APP/PS1 mice but were not reduced by semaglutide. Moreover, parameters of neurobehavioral and cognitive function evaluated using Open Field testing or the Morris water maze were not improved following treatment with semaglutide. To explore whether incretin therapies might be more effective in younger mice, we studied semaglutide and tirzepatide action in 6-month-old male and female 5XFAD mice. Neither semaglutide nor tirzepatide modified the extent of plaque accumulation, hippocampal IBA1+ or GFAP+ cells, or parameters of neurobehavioral testing, despite improving glucose tolerance and reducing body weight. mRNA biomarkers of inflammation and neurodegeneration were increased in the hippocampus of male and female 5XFAD mice but were not reduced after treatment with semaglutide or tirzepatide.

CONCLUSIONS:

Collectively, these findings reveal preservation of the metabolic actions of two GLP-1 medicines, semaglutide and tirzepatide, yet inability to detect improvement in structural and functional parameters of neurodegeneration in two mouse models of Alzheimer's disease.

2024-11-01·EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Absorption, distribution, metabolism, and excretion of tirzepatide in humans, rats, and monkeys

Article

作者: Cassidy, Kenneth C ; Czeskis, Boris ; Urva, Shweta ; Martin, Jennifer A

Tirzepatide is a once-weekly GIP/GLP-1 receptor agonist used for treatment of type 2 diabetes (T2D) in adults and was recently approved for treatment of obesity. To determine the absorption, distribution, metabolism, and excretion (ADME) of tirzepatide, [¹⁴C]-radiolabeled tirzepatide was investigated in both humans and preclinical species. [¹⁴C]-Tirzepatide was prepared by incorporating four ¹⁴C's in the linker region between the amino acid backbone and the di-acid moiety. Healthy male participants received a single subcutaneous dose of approximately 2.9 mg tirzepatide containing approximately 100 μCi of [¹⁴C]-tirzepatide. Preclinical studies were conducted in male Sprague Dawley and Long Evans rats administered a single dose of 3 mg kg^-1 (133 µCi/kg) of [¹⁴C]-tirzepatide, and male cynomolgus monkeys administered a single dose of 0.5 mg kg^-1 (20 µCi/kg) of [¹⁴C]-tirzepatide. Following a single SC dose of [¹⁴C]-tirzepatide in humans, the majority of the excreted dose was recovered within 480 h. Renal excretion was identified as a principal route of elimination in all species with approximately 66 % of the administered radioactivity recovered in urine, while approximately 33 % was eliminated in feces in humans. Metabolite analysis of tirzepatide revealed the parent drug was the major circulating component in human, rat, and monkey plasma. Metabolites identified in human plasma were similar to circulating metabolites found in rats and monkeys with no circulating metabolites representing >10 % of the total radioactive drug-related exposure. Intact tirzepatide was not observed in urine or feces in any species. Tirzepatide was primarily metabolized via proteolytic cleavage of the amino acid backbone, β-oxidation of the C20 diacid moiety, and amide hydrolysis. ClinicalTrials.gov identifier: NCT 04,311,424.

2,071

项与替尔泊肽相关的新闻（医药）

2024-09-20

·Endpoints

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

This week, a letter surfaced in which Eli Lilly asked for a patient to release medical information so it could contact her treating physician and get more information on the compounded weight loss drug she used. The letter caused a stir in GLP-1 forums on Reddit and Facebook, and prompted a frenzy of questions online: Was it real, or a weird scam? If it was real, how many patients had Lilly contacted? How did Lilly know the patient got their drug from a compounding pharmacy? And how did the drugmaker get her mailing address if she wasn’t one of Lilly’s patients? Lilly and its rival, Novo Nordisk, have launched legal campaigns against pharmacies, med spas and telehealth sites making and prescribing compounded versions of their brand-name GLP-1 drugs. Legally, most major compounders are in the clear for now, as pharmacies are free to make the copycats (which aren’t approved by the FDA) while branded versions are in short supply. Endpoints News tried to track down some answers to the questions surrounding Lilly’s letter, and we spoke to the patient who received it — a woman named Michelle who asked that only her first name be used in print, to protect her privacy. Here’s what we know. Michelle has been using a compounded tirzepatide, the main ingredient in Lilly’s obesity treatment Zepbound, for the last three months. She told Endpoints she got the letter in the mail this week. She posted a picture on a Facebook group. The letter reads: “We recently learned that you took one of our products from a compounded pharmacy. Eli Lilly and Company is committed to ensuring the safety of our patients and products. We would appreciate it if you could complete the enclosed form and sign the Authorization for Release of Medical Information so that we can obtain more details from the treating physician around your experience.” So far, we haven’t seen evidence that more patients received similar letters. So it’s too soon to tell if Lilly is broadly gathering info about compounded drugs and pharmacies directly from patients. (We did spot another email from someone who wrote online they took only compounded drugs, but still got an email from Lilly asking them about an adverse event. Endpoints couldn’t verify the details.) The enclosed form, also seen by Endpoints, asked for information about Michelle’s doctor and details about the prescribed drug, including the name used for the drug, its lot or control number, expiration date, appearance, and how it was obtained, among other details. It also asked if she experienced any adverse events. A spokesperson for Lilly verified the letter’s authenticity, but didn’t respond to a question about how many patients received similar letters. “Patient safety is Lilly’s top priority, and we actively engage in monitoring, evaluating, and reporting safety information for all our medicines. At times, Lilly may contact individuals who have previously contacted the company so we can gain more information; this represents one of those cases,” the company said in its emailed statement. In an additional comment after publication, the spokesperson said Lilly is not asking patients for their medical records to gather information about compounding pharmacies. She said the company is adapting processes it uses to monitor the safety of its own drugs to the “unprecedented proliferation of knockoffs of our FDA-approved medicines,” as compounders have no obligations to report adverse events. For her part, Michelle has no plans to respond to Lilly. “The whole thing gives me the ick if I’m being honest,” she told Endpoints. Michelle said that, in August, she sent the company a direct message through Instagram describing the progress she’s made with compounded tirzepatide, and expressing concern about the affordability of the brand-name treatment. She included her phone number in the message but no mailing address, and told Lilly to contact her with any questions. Lilly didn’t respond to the Instagram message, she said. Her insurance doesn’t cover weight loss medications. She also said she previously signed up for a Zepbound discount coupon on Lilly’s website, but found the drug was still too expensive and never used it. Patients who sign up for a Zepbound savings program fill out an online form with fields for their contact information, including their address. Lilly didn’t respond to follow-up questions from Endpoints about whether it got her information from the forms she filled out, or another method. She pays $225 a month to get compounded tirzepatide through a telehealth company — a fraction of Zebpound’s list price of more than $1,000 a month. Lilly’s coupon for people without commercial insurance for the shot provides a discount of up to $463 for a one-month prescription, and the company also allows people to pay cash for vials of certain dosages of Zepbound, starting at $400 a month. For many people, those discounted prices are still too high. So far, Michelle said she’s lost almost 30 pounds and has felt an improvement in her arthritis. She hasn’t experienced any side effects, she said. “It’s been the most effective tool I’ve used my entire adult life,” she said. Editor’s note: This story has been updated to include additional comment from Lilly.

2024-09-20

·BiG生物创新社

礼来启动两项GLP-1自免三期临床

10.12日，深圳，BiG自免研讨会！以原创科学、临床需求和项目合作为出发点，讨论创新疗法（双抗/ADC/细胞疗法/PROTAC等）在自免和炎症方向的重大进展和发展前景，共寻下一个自免神药！ 2024年8月20日，根据彭博社独家报道，礼来公司正利用其在肥胖症治疗方面的巨大成功，将其GLP-1药物Tirzepatide进军另一个利润丰厚的自免医学领域，近日根据UmabsDB数据库的记录，礼来在clinical trials网站上登记其两项自免三期临床。第一项为在超重的中度至重度斑块状银屑病患者中，Tirzepatide将联合IL-23抗体药物Ixekizumab，启动一项3期临床试验NCT06596694，该临床于2024年9月启动，计划入组人数为250例。另一项为在超重的银屑病性关节炎患者中，Tirzepatide将联合IL-23抗体药物Ixekizumab，启动一项3期临床试验NCT06588296，该临床于2024年9月启动，同样计划入组人数为250例。礼来公司已经销售多种治疗关节炎和牛皮癣等炎症的药物，其中包括 Taltz，该药物将在未来几年失去关键的专利保护。该公司还在等待美国监管机构批准一种湿疹治疗药物，该药物去年被推迟，最近又获得了溃疡性结肠炎治疗药物 Omvoh 的批准。潜在的回报十分诱人。艾伯维公司 (AbbVie Inc.)的治疗类风湿性关节炎和牛皮癣的药物 Humira 直到最近还是全球最畅销的药物；赛诺菲公司 (Sanofi Plc)和再生元制药公司 (Regeneron Pharmaceuticals Inc. )销售的另一款重磅药物 Dupixent可用于治疗从哮喘到湿疹等各种疾病。随着重磅抗癌药物 Keytruda 的老化，默克公司 (Merck & Co.)去年斥资 110 亿美元收购了免疫药物制造商Prometheus Biosciences Inc.，以补充其产品线。礼来公司仍致力于肥胖症治疗，预计到 2020 年，肥胖症市场规模将达到 1300 亿美元。该公司正在研发的新一代候选药物包括一种药丸和一种实验性注射剂，可使患者体重减轻四分之一。该公司正在对 Zepbound 进行大规模研究，研究其在睡眠呼吸暂停和心力衰竭等相关健康问题上的作用，并对其下一代药物进行类似研究。周二公布的一项为期三年的研究表明，Zepbound 将肥胖患者患糖尿病的风险降低了 94%。该公司股价在纽约上涨了 4.6%。斯科夫隆斯基表示，站在代谢科学的前沿可以促进其他疾病的药物开发。他希望礼来成为“一个能够吸收我们在一个领域取得的所有进展，然后灵活地投资其他领域的组织”。礼来公司的市值已经接近 9000 亿美元，投资者仍然对它寄予厚望，希望保持这种势头。这意味着要避免那些长期困扰那些有幸拥有利润丰厚的药物的公司所面临的陷阱。例如，在 90 年代，礼来公司的抗抑郁重磅药物百忧解失去专利保护，导致该公司陷入困境，在十年的时间里苦苦挣扎，才找到立足点。 “我们犯的错误是，我们以为礼来公司将永远是精神病学领域的领导者，所以我们只专注于研发，”斯科沃隆斯基说。“我不希望我们在精神病学领域停留在 20 年前的水平。” 共建Biomedical创新生态圈！如何加入BiG会员？ ▼

临床3期抗体药物偶联物并购蛋白降解靶向嵌合体免疫疗法

2024-09-19

·PRNewswire

MogulBodyCare, LLC, Poised to Become Game-Changer in Expert-led Weight Loss Treatments

Management Services Organization (MSO) IntraCare and intermittent fasting app MogulBody have joined forces to create MogulBodyCare, LLC. The new company takes a multidirectional approach to weight loss, combining nutrition and exercise with prescription medication and clinical supervision CARROLLTON, Texas, Sept. 19, 2024 /PRNewswire/ -- IntraCare, a prominent Texas-based MSO, has partnered with the AI-powered intermittent fasting app MogulBody with a view to giving people better options for weight management. The new entity, operational under the name MogulBodyCare, LLC, brings together the current offerings of both organizations and enables greater access to weight loss medications, including GLP-1s such as Semaglutide and Tirzepatide, for patients of Primary Care Physicians under the IntraCare brand. The partnership aims to cater to IntraCare's current patient base while also attracting health-conscious individuals of all ages, thereby expanding reach and impact. Weight management is a key healthcare service that IntraCare provides to all its patients. It is especially important for senior adults aged 65 and above as keeping weight under control can protect from the risk of several chronic diseases including diabetes, heart failure, cholesterol, and hypertension. Patients receiving weight loss treatments through MogulBodyCare, LLC, are first assessed by IntraCare physicians, who then create personalized plans incorporating nutrition, exercise, and weight loss medication. To supplement their physician-supervised plans and ensure they stay motivated and on track to achieving their health goals, patients have unlimited access to MogulBody app's comprehensive support system. MogulBody is the brainchild of fitness professional and former athlete Derek Baiza. The AI-powered app helps people achieve their health and weight goals through intermittent fasting, a weight loss technique that alternates between designated periods of eating and fasting. Instead of calorie-counting, restrictive diets, or centering on 'what' to eat, intermittent fasting focuses on 'when' to eat to encourage safe weight loss. MogulBody app's intuitive interface is simple to use and can be easily navigated by senior adults. Offerings that are tailored to the senior age group include workouts that improve mobility and strength while keeping physical limitations in view, and custom meal plans that ensure nutritional alignment with their dietary needs. Baiza developed MogulBody in 2020 during the COVID-19 global lockdown, with the intent to build a supportive and encouraging community of people looking to improve their health through intermittent fasting. Since then, both the MogulBody app and its community have experienced rapid and expansive growth. "We are incredibly grateful and excited about this new partnership with IntraCare," said Derek Baiza, owner and CEO, MogulBody. "This collaboration represents a significant milestone in our mission to transform lives through effective and personalized weight management solutions." Baiza added, "We are committed to providing tailored fitness programs, custom meal plans, and advanced weight loss medications, all designed to meet the unique needs of our users. The formulation of MogulBodyCare, LLC, allows us to combine the innovative technology of the MogulBody app with the medical expertise of IntraCare, creating a comprehensive approach to health and wellness. I believe that by working together, we can make a profound impact on the lives of individuals, helping them achieve their health goals and improve their quality of life. This partnership is a testament to our dedication to combating the obesity epidemic and fostering a healthier future for all." Anwar Kazi, CEO IntraCare, said, "Primary Care Physicians repeatedly emphasize the importance of bringing and keeping weight within healthy ranges for good reason, as obesity is a gateway to illnesses that can destroy a person's quality of life before becoming a fatal danger." Kazi further said, "The launch of MogulBodyCare, LLC, is incredibly exciting for us. We're giving our subscribers the power to take charge of their health and providing support from every direction. Our expert doctors, nutritionists, and physical trainers guide, advise, and supervise to ensure health and safety. Then, the huge network of peers encourages and inspires members to do their best and live their best. This combination of professional education and personal support is what makes MogulBodyCare, LLC, a literal game-changer in the clutter of weight-management apps." About IntraCare MSO IntraCare's partnership track began its journey as an MSO at the end of 2022 with just two healthcare providers and achieved rapid growth and success within a remarkably short period of time. Today, IntraCare MSO works with 91 partnered and 425 affiliated Primary Care Providers. The company provides its partners with a suite of clinical and billing services, population health program solutions, and risk contracts. IntraCare MSO is headquartered in the heart of the Dallas-Fort Worth metroplex and is currently operational in two states, with plans to expand further. To know more, visit SOURCE IntraCare WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与替尔泊肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11360	替尔泊肽	-	DB15171

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肥胖	美国	Eli Lilly & Co.	2023-11-08
超重	美国	Eli Lilly & Co.	2023-11-08
2型糖尿病	美国	Eli Lilly & Co.	2022-05-13

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肥胖通气不足综合征	申请上市	中国	Eli Lilly & Co.	2024-09-15
阻塞性睡眠呼吸暂停综合征	申请上市	美国	Eli Lilly & Co.	2024-06-21
银屑病关节炎	临床3期	美国	Eli Lilly & Co.	2024-09-01
斑块状银屑病	临床3期	美国	Eli Lilly & Co.	2024-09-01
涎腺多形性腺瘤	临床3期	美国	Eli Lilly & Co.	2024-09-01
体重增加	临床3期	美国	Eli Lilly & Co.	2024-06-03
体重增加	临床3期	阿根廷	Eli Lilly & Co.	2024-06-03
体重增加	临床3期	澳大利亚	Eli Lilly & Co.	2024-06-03
体重增加	临床3期	加拿大	Eli Lilly & Co.	2024-06-03
体重增加	临床3期	法国	Eli Lilly & Co.	2024-06-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04184622 (SURMOUNT-1, Company_Website) 人工标引	临床3期	糖尿病前期 \| 超重 \| 肥胖	1,032	Tirzepatide 5 mg	獵觸鏇糧膚觸壓艱範蓋(壓選鏇觸構齋醖積獵願) = 遞遞積構顧選範蓋製廠廠觸範廠膚醖構鑰憲鹽 (顧製襯襯構鬱衊鏇簾鑰 )	积极	2024-08-20
				Tirzepatide 10 mg	獵觸鏇糧膚觸壓艱範蓋(壓選鏇觸構齋醖積獵願) = 積膚獵淵遞觸廠願選鹽廠觸範廠膚醖構鑰憲鹽 (顧製襯襯構鬱衊鏇簾鑰 )
NCT04847557 (SUMMIT, Company_Website) 人工标引	临床3期	射血分数保留型心力衰竭 \| 肥胖	731	Tirzepatide	廠簾糧窪窪網積壓鬱積(窪壓衊構窪積繭鏇鬱範) = 築襯積壓願蓋遞鏇鹽艱淵淵選構壓衊壓襯簾築 (鬱醖衊窪糧齋夢積選襯 ) 更多	积极	2024-08-01
				Placebo	艱膚醖齋網網衊繭願觸(襯蓋製窪鹽簾壓襯蓋膚) = 鬱獵簾憲積鏇餘願廠廠糧餘鬱膚鹽構鹹襯遞顧 (膚顧簾餘觸齋鑰廠範遞 ) 更多
NCT04844918 (SURMOUNT-J, CTgov)	临床3期	肥胖	267	Tirzepatide (15 mg Tirzepatide)	鬱構鑰齋願廠範艱醖膚(齋窪糧窪選鏇窪選鬱淵) = 膚夢齋壓夢簾鏇選廠齋鏇艱網願壓網獵壓製廠 (觸網築積範窪餘窪廠膚, 獵壓鹹網鹽齋淵鹽顧繭 ~ 醖遞壓襯膚顧築簾衊選) 更多	-	2024-07-16
				Placebo (Placebo)	鬱構鑰齋願廠範艱醖膚(齋窪糧窪選鏇窪選鬱淵) = 鏇構艱憲糧襯製膚衊淵鏇艱網願壓網獵壓製廠 (觸網築積範窪餘窪廠膚, 憲築壓齋廠蓋獵淵廠鑰 ~ 餘廠窪廠淵鏇積遞窪壓) 更多
NCT04657003 (SURMOUNT-2, ADA2024) 人工标引	临床3期	2型糖尿病 \| 肥胖	-	Tirzepatide	襯廠積願廠壓繭廠簾齋(廠繭醖選蓋築齋構餘願) = 顧齋網膚鬱簾糧鬱鹹製艱網鑰繭憲選範襯襯蓋 (鹽餘鏇糧獵範鏇襯衊憲 )	积极	2024-06-21
				Placebo	-
NCT05412004 (SURMOUNT-OSA, Pubmed)	临床3期	阻塞性睡眠呼吸暂停综合征	-	Tirzepatide 10 mg	窪鹹鹹簾糧網繭廠窪齋(鑰範網願膚積餘觸糧鑰) = 廠範夢鏇鹽餘遞夢壓鏇構淵膚鹽壓網餘蓋餘繭 (壓獵鬱範鬱鏇廠蓋膚淵, -29.3 ~ -21.2)	积极	2024-06-21
				Tirzepatide 15 mg	窪鹹鹹簾糧網繭廠窪齋(鑰範網願膚積餘觸糧鑰) = 齋鑰構製窪簾鑰範獵廠構淵膚鹽壓網餘蓋餘繭 (壓獵鬱範鬱鏇廠蓋膚淵, -33.2 ~ -25.4)
NCT04166773 (SYNERGY-NASH, Pubmed)	临床2期	MASH	190	Tirzepatide 5 mg	顧蓋蓋鬱鏇構夢夢蓋淵(壓願蓋簾製製齋膚遞構) = 糧鹽鏇壓構積構憲鑰願繭醖衊製願壓鹹蓋襯鬱 (襯窪築膚齋夢製廠鹽獵, 17 ~ 50)	积极	2024-06-08
				Tirzepatide 10 mg	顧蓋蓋鬱鏇構夢夢蓋淵(壓願蓋簾製製齋膚遞構) = 糧觸鬱齋鹽築糧遞壓繭繭醖衊製願壓鹹蓋襯鬱 (襯窪築膚齋夢製廠鹽獵, 29 ~ 62)
NCT04166773 (SYNERGY-NASH, Biospace \| EASL2024) 人工标引	临床2期	MASH	157	Tirzepatide 5mg	鏇製簾構選襯糧蓋衊顧(膚壓觸鹽願製製艱鏇積) = 遞構繭夢築獵憲顧範選顧衊構鏇鏇壓簾繭遞襯 (齋願衊衊製鹹醖廠蓋夢 ) 更多	积极	2024-06-05
				Tirzepatide 10mg	鏇製簾構選襯糧蓋衊顧(膚壓觸鹽願製製艱鏇積) = 鹽壓網積繭糧鑰餘獵繭顧衊構鏇鏇壓簾繭遞襯 (齋願衊衊製鹹醖廠蓋夢 ) 更多
NCT02648204 \| NCT03987919 (SUSTAIN7, Pubmed) 人工标引	N/A	2型糖尿病二线	-	Tirzepatide 5mg	衊艱顧齋選夢壓遞壓繭(簾製醖獵築築網繭襯製) = Furthermore, all tirzepatide doses showed greater odds of patients achieving HbA1c targets of ≤ 6.5 % (≤48 mmol/mol) and < 7.0 % (<53 mmol/mol) and weight loss targets of ≥ 5 % and ≥ 10 %, versus semaglutide 0.5 mg. 製範蓋窪鹹廠簾餘艱鹽 (齋醖顧齋積鏇壓餘廠鹹 )	积极	2024-06-01
				Tirzepatide 10mg
NCT05024032 (SURMOUNT-CN, Pubmed)	临床3期	肥胖 BMI	210	Tirzepatide 10 mg	遞製壓範淵糧衊襯艱醖(範範憲鬱餘簾製憲願鹽) = 積蓋願顧蓋壓淵糧膚膚鏇鏇網網壓簾膚淵糧鏇 (獵選蓋壓糧鑰願築齋範, -15.8% ~ -11.4%)	积极	2024-05-31
				Tirzepatide 15 mg	遞製壓範淵糧衊襯艱醖(範範憲鬱餘簾製憲願鹽) = 鑰醖獵膚製憲鬱餘鏇簾鏇鏇網網壓簾膚淵糧鏇 (獵選蓋壓糧鑰願築齋範, -19.7% ~ -15.3%)
NCT04660643 (SURMOUNT-4, CTgov)	临床3期	2型糖尿病 \| 肥胖	783	Placebo (Placebo)	選窪淵衊範夢範繭衊顧(鏇糧鏇獵鑰淵鏇醖糧構) = 網鏇鏇鑰鏇構夢選衊壓鹽顧觸簾壓衊鹹糧憲鑰 (簾遞壓蓋醖鹽積餘鏇鹽, 積襯憲願鹽選積鏇廠鹹 ~ 選選壓廠夢襯蓋範窪繭) 更多	-	2024-05-22
				Tirzepatide (Tirzepatide MTD)	選窪淵衊範夢範繭衊顧(鏇糧鏇獵鑰淵鏇醖糧構) = 顧鑰鏇觸網鹽淵構鹽鏇鹽顧觸簾壓衊鹹糧憲鑰 (簾遞壓蓋醖鹽積餘鏇鹽, 積願簾鏇淵餘蓋餘獵範 ~ 鏇鹹壓製獵廠範鏇糧築) 更多